Holen Sie sich die Stockscreener-App
1.72
6.01%
-0.11
Handel nachbörslich:
1.72
Schlusskurs vom Vortag:
$1.83
Offen:
$1.8
24-Stunden-Volumen:
1.27M
Relative Volume:
0.59
Marktkapitalisierung:
$143.98M
Einnahmen:
$32.31M
Nettoeinkommen (Verlust:
$-237.09M
KGV:
-0.5972
EPS:
-2.88
Netto-Cashflow:
$-219.11M
1W Leistung:
+10.97%
1M Leistung:
+10.97%
6M Leistung:
-23.21%
1J Leistung:
-66.73%
1-Tages-Spanne:
$1.70
$1.81
1-Wochen-Bereich:
$1.5646
$1.9499
52-Wochen-Spanne:
$0.9101
$6.22
Editas Medicine Inc Stock (EDIT) Company Profile
Firmenname
Editas Medicine Inc
Sektor
Branche
Telefon
617-401-9000
Adresse
11 HURLEY ST., CAMBRIDGE, MA
Vergleichen Sie EDIT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
1.72 | 129.75M | 32.31M | -237.09M | -219.11M | -2.88 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-13 | Herabstufung | Truist | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-11-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-05-09 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-10-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Eingeleitet | Citigroup | Neutral |
| 2022-12-06 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-11-18 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Eingeleitet | BofA Securities | Neutral |
| 2021-10-19 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-09-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Hochstufung | Truist | Hold → Buy |
| 2021-08-05 | Hochstufung | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Eingeleitet | Goldman | Sell |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Herabstufung | Truist | Buy → Hold |
| 2021-01-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Eingeleitet | Robert W. Baird | Underperform |
| 2020-06-18 | Fortgesetzt | SunTrust | Buy |
| 2020-02-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-10 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Outperform |
| 2018-05-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-02-13 | Eingeleitet | CLSA | Underperform |
| 2018-01-23 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Hold |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-10 | Hochstufung | Jefferies | Hold → Buy |
| 2016-06-02 | Eingeleitet | Jefferies | Hold |
| 2016-02-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-29 | Eingeleitet | JP Morgan | Neutral |
| 2016-02-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
Millennium Management LLC Cuts Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
Two Sigma Advisers LP Grows Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Purchased by BNP Paribas Financial Markets - Defense World
Northern Trust Corp Has $884,000 Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
Brokerages Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $5.36 - MarketBeat
Editas Medicine (EDIT) Joins Russell Microcap Index - GuruFocus
Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha
CRISPR and Cas Genes Market Set to Witness Significant Growth - openPR.com
Editas Medicine’s SWOT analysis: gene editing stock pivots amid challenges By Investing.com - Investing.com Canada
Editas Medicine’s SWOT analysis: gene editing stock pivots amid challenges - Investing.com Australia
1 Stock Down 97% That Could Double, According to Wall Street - The Globe and Mail
Tang Capital Management LLC Purchases Shares of 400,000 Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of “Hold” by Brokerages - Defense World
Jacobs Levy Equity Management Inc. Has $900,000 Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine, Inc.'s (NASDAQ:EDIT) Price Is Right But Growth Is Lacking After Shares Rocket 28% - simplywall.st
Editas Medicine (EDIT) Shifts Focus to In Vivo Programs | EDIT S - GuruFocus
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Editas Medicine (EDIT) Shifts Focus to In Vivo Programs | EDIT Stock News - GuruFocus
Stifel Financial Corp Sells 287,718 Shares of Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Robert W. Baird Cuts Editas Medicine (NASDAQ:EDIT) Price Target to $4.00 - MarketBeat
Balyasny Asset Management L.P. Grows Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Crispr Therapeutics Products 2025: Therapies, MOA Insights, - openPR.com
Editas Medicine (NASDAQ:EDIT) Stock Rating Upgraded by StockNews.com - Defense World
Editas Medicine: A Cautionary Tale for Investors - AOL.com
Raymond James Financial Inc. Invests $303,000 in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory - Pharma Voice
Robert W. Baird Issues Pessimistic Forecast for Editas Medicine (NASDAQ:EDIT) Stock Price - Defense World
Editas Medicine Reports Q1 2025 Progress and Financials - TipRanks
Editas Medicine: A Cautionary Tale For Investors - Barchart.com
Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y - MSN
Editas Medicine to Present in vivo HSC Delivery, Editing, and Bi - GuruFocus
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June - The Manila Times
Editas Medicine to Present in vivo HSC Delivery, Editing, - GlobeNewswire
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the ... - Bluefield Daily Telegraph
Editas optimistic on CRISPR patent outcome after appeal By Investing.com - Investing.com Nigeria
Editas Medicine (EDIT) Advances Gene Editing for Blood Disorders with Promising Results | EDIT Stock News - GuruFocus
Editas Medicine Reports New In Vivo Data Highlighting The Potential Of Editas' Gene Upregulation Strategy In Hscs At The American Society Of Gene And Cell Therapy Annual Meeting - marketscreener.com
Editas Medicine Reports New In Vivo Data Highlighting the Potent - GuruFocus
Editas Medicine First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Editas Medicine reports new in vivo data on HBG1/2 promoter editing in HSCs - TipRanks
Editas Medicine Unveils Promising Gene Editing Data - TipRanks
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting - The Manila Times
Editas Medicine Reports Promising In Vivo Gene Editing Results for Sickle Cell Disease and Beta Thalassemia at ASGCT Annual Meeting - Nasdaq
Editas Medicine Reports New In Vivo Data Highlighting the - GlobeNewswire
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting - TradingView
Editas Medicine at BofA Securities 2025: In Vivo Gene Editing Focus - Investing.com Canada
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by Dimensional Fund Advisors LP - Defense World
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by Wells Fargo & Company MN - MarketBeat
Breakthrough: Editas Medicine's New Gene Therapy Data Shows 48% Success Rate for Sickle Cell Disease Treatment - Stock Titan
Editas Medicine Reports New In Vivo Proof of Concept Data - GlobeNewswire
Transcript : Editas Medicine, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 05 - marketscreener.com
Finanzdaten der Editas Medicine Inc-Aktie (EDIT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):